| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
,
*
DNAX Research Institute of Molecular and Cellular Biology, Inc., Palo Alto, CA 94304;
Canji Inc., San Diego, CA 92121; and Departments of
Molecular Microbiology and Immunology and
Neurology, University of Southern California School of Medicine, Los Angeles, CA 90033
Multiple sclerosis, an inflammatory, demyelinating disease of the CNS currently lacks an effective therapy. We show here that CNS inflammation and clinical disease in experimental autoimmune encephalomyelitis, an experimental model of multiple sclerosis, could be prevented completely by a replication-defective adenovirus vector expressing the anti-inflammatory cytokine IL-10 (replication-deficient adenovirus expressing human IL-10), but only upon inoculation into the CNS where local infection and high IL-10 levels were achieved. High circulating levels of IL-10 produced by i.v. infection with replication-deficient adenovirus expressing human IL-10 was ineffective, although the immunological pathways for disease are initiated in the periphery in this disease model. In addition to this protective activity, intracranial injection of replication-deficient adenovirus expressing human IL-10 to mice with active disease blocked progression and accelerated disease remission. In a relapsing-remitting disease model, IL-10 gene transfer during remission prevented subsequent relapses. These data help explain the varying outcomes previously reported for systemic delivery of IL-10 in experimental autoimmune encephalomyelitis and show that, for optimum therapeutic activity, IL-10 must either access the CNS from the peripheral circulation or be delivered directly to it by strategies including the gene transfer described here.
This article has been cited by other articles:
|
|
 |
|
  M. Batten, N. M. Kljavin, J. Li, M. J. Walter, F. J. de Sauvage, and N. Ghilardi Cutting Edge: IL-27 Is a Potent Inducer of IL-10 but Not FoxP3 in Murine T Cells J. Immunol., March 1, 2008; 180(5): 2752 - 2756. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Kleinschek, A. M. Owyang, B. Joyce-Shaikh, C. L. Langrish, Y. Chen, D. M. Gorman, W. M. Blumenschein, T. McClanahan, F. Brombacher, S. D. Hurst, et al. IL-25 regulates Th17 function in autoimmune inflammation J. Exp. Med., January 22, 2007; 204(1): 161 - 170. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Qin, C. A. Wilson, K. L. Roberts, B. J. Baker, X. Zhao, and E. N. Benveniste IL-10 Inhibits Lipopolysaccharide-Induced CD40 Gene Expression through Induction of Suppressor of Cytokine Signaling-3 J. Immunol., December 1, 2006; 177(11): 7761 - 7771. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. P. Bailey, M. Kashyap, L. A. Bouton, P. J. Murray, and J. J. Ryan Interleukin-10 induces apoptosis in developing mast cells and macrophages J. Leukoc. Biol., September 1, 2006; 80(3): 581 - 589. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Miyamoto, C. I. Kingsley, X. Zhang, C. Jabs, L. Izikson, R. A. Sobel, H. L. Weiner, V. K. Kuchroo, and A. H. Sharpe The ICOS Molecule Plays a Crucial Role in the Development of Mucosal Tolerance J. Immunol., December 1, 2005; 175(11): 7341 - 7347. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. D. Powell, T. L. Papenfuss, M. A. McClain, I. E. Gienapp, T. M. Shawler, A. R. Satoskar, and C. C. Whitacre Cutting Edge: Macrophage Migration Inhibitory Factor Is Necessary for Progression of Experimental Autoimmune Encephalomyelitis J. Immunol., November 1, 2005; 175(9): 5611 - 5614. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Kihara, S. Ishii, Y. Kita, A. Toda, A. Shimada, and T. Shimizu Dual phase regulation of experimental allergic encephalomyelitis by platelet-activating factor J. Exp. Med., September 19, 2005; 202(6): 853 - 863. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. McGeachy, L. A. Stephens, and S. M. Anderton Natural Recovery and Protection from Autoimmune Encephalomyelitis: Contribution of CD4+CD25+ Regulatory Cells within the Central Nervous System J. Immunol., September 1, 2005; 175(5): 3025 - 3032. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. C. Dowdell, D. J. Cua, E. Kirkman, and S. A. Stohlman NK Cells Regulate CD4 Responses Prior to Antigen Encounter J. Immunol., July 1, 2003; 171(1): 234 - 239. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Asadullah, W. Sterry, and H. D. Volk Interleukin-10 Therapy--Review of a New Approach Pharmacol. Rev., June 1, 2003; 55(2): 241 - 269. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Trabattoni, M. Saresella, M. Biasin, A. Boasso, L. Piacentini, P. Ferrante, H. Dong, R. Maserati, G. M. Shearer, L. Chen, et al. B7-H1 is up-regulated in HIV infection and is a novel surrogate marker of disease progression Blood, April 1, 2003; 101(7): 2514 - 2520. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. A. Braciak, B. Pedersen, J. Chin, C. Hsiao, E. S. Ward, I. Maricic, A. Jahng, F. L. Graham, J. Gauldie, E. E. Sercarz, et al. Protection Against Experimental Autoimmune Encephalomyelitis Generated by a Recombinant Adenovirus Vector Expressing the V{beta}8.2 TCR Is Disrupted by Coadministration with Vectors Expressing Either IL-4 or -10 J. Immunol., January 15, 2003; 170(2): 765 - 774. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G-X Zhang, M Kishi, H Xu, and A Rostami Mature bone marrow-derived dendritic cells polarize Th2 response and suppress experimental autoimmune encephalomyelitis Multiple Sclerosis, December 1, 2002; 8(6): 463 - 468. [Abstract] [PDF]
|
|
|
|
|
|
K A Karls, P W Denton, and R W Melvold Susceptibility to Theiler's murine encephalomyelitis virus-induced demyelinating disease in BALB/cAnNCr mice is related to absence of a CD4+ T-cell subset Multiple Sclerosis, December 1, 2002; 8(6): 469 - 474. [Abstract] [PDF]
|
|
|
|
|
|
K. L. Legge, R. K. Gregg, R. Maldonado-Lopez, L. Li, J. C. Caprio, M. Moser, and H. Zaghouani On the Role of Dendritic Cells in Peripheral T Cell Tolerance and Modulation of Autoimmunity J. Exp. Med., July 15, 2002; 196(2): 217 - 227. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G.-X. Zhang, H. Xu, M. Kishi, D. Calida, and A. Rostami The Role of IL-12 in the Induction of Intravenous Tolerance in Experimental Autoimmune Encephalomyelitis J. Immunol., March 1, 2002; 168(5): 2501 - 2507. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
